Benzamide, 4-chloro-N-[(1R)-1-[cis-4-(6-fluoro-4-quinolinyl)cyclohexyl]ethyl]- manufacturers
- BMS-986242
-
- $86.00 / 1mg
-
2025-04-28
- CAS:1923844-48-7
- Min. Order:
- Purity: 98.25%
- Supply Ability: 10g
|
| | Benzamide, 4-chloro-N-[(1R)-1-[cis-4-(6-fluoro-4-quinolinyl)cyclohexyl]ethyl]- Basic information |
| Product Name: | Benzamide, 4-chloro-N-[(1R)-1-[cis-4-(6-fluoro-4-quinolinyl)cyclohexyl]ethyl]- | | Synonyms: | Benzamide, 4-chloro-N-[(1R)-1-[cis-4-(6-fluoro-4-quinolinyl)cyclohexyl]ethyl]-;BMS-986242;glucuronidation,potent,Indoleamine 2,3-Dioxygenase (IDO),cancer,Inhibitor,BMS 986242,inhibit,BMS-986242,active,selective,orally;4-chloro-N-[(1R)-1-[(1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl]ethyl]benzamide;BMS-986242, 10 mM in DMSO | | CAS: | 1923844-48-7 | | MF: | C24H24ClFN2O | | MW: | 410.91 | | EINECS: | | | Product Categories: | | | Mol File: | 1923844-48-7.mol | ![Benzamide, 4-chloro-N-[(1R)-1-[cis-4-(6-fluoro-4-quinolinyl)cyclohexyl]ethyl]- Structure](CAS/20210305/GIF/1923844-48-7.gif) |
| | Benzamide, 4-chloro-N-[(1R)-1-[cis-4-(6-fluoro-4-quinolinyl)cyclohexyl]ethyl]- Chemical Properties |
| Boiling point | 593.0±40.0 °C(Predicted) | | density | 1.228±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 250 mg/mL (608.41 mM; Need ultrasonic) | | form | Solid | | pka | 14.09±0.46(Predicted) | | color | White to off-white |
| | Benzamide, 4-chloro-N-[(1R)-1-[cis-4-(6-fluoro-4-quinolinyl)cyclohexyl]ethyl]- Usage And Synthesis |
| Uses | BMS-986242 is an orally active, potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor. BMS-986242 can be used for the research of cancer[1]. | | Biological Activity | BMS-986242 is an orally active, potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor. BMS-986242 can be used for the research of cancer[1].
BMS-986242 is more prone to oxidative metabolism and less susceptible to glucuronidation. BMS-986242 shows IC50>25 μM for all targets except nAChR a1 (IC50=12.3 μM) and nAChR a7 (IC50>6 μM with ～20 % max inhibition)[1].
BMS-986242 (3~30 mg/kg; p.o.; 0~24 hours) exhibits dose-proportional exposure and a statistically significant reduction in kynurenine concentration in the tumor at all three doses[1]. | | in vivo | BMS-986242 (3~30 mg/kg; p.o.; 0~24 hours) exhibits dose-proportional exposure and a statistically significant reduction in kynurenine concentration in the tumor at all three doses[1]. | Animal Model: | nu/nu Mouse[1] | | Dosage: | 3~30 mg/kg | | Administration: | P.o. | | Result: | Exhibited dose-proportional exposure and a statistically significant reduction in kynurenine concentration in the tumor at all three doses.
|
| | IC 50 | IDO1 | | References | [1]. Cherney EC, et al. Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1. ACS Med Chem Lett. 2021;12(2):288-294. Published 2021 Jan 28. |
| | Benzamide, 4-chloro-N-[(1R)-1-[cis-4-(6-fluoro-4-quinolinyl)cyclohexyl]ethyl]- Preparation Products And Raw materials |
|